{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:49:28Z","timestamp":1794667768905,"version":"4.9.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["20190201054JC"],"award-info":[{"award-number":["20190201054JC"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020230","name":"Health Commission of Jilin Province","doi-asserted-by":"publisher","award":["2021JC077"],"award-info":[{"award-number":["2021JC077"]}],"id":[{"id":"10.13039\/501100020230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.biopha.2022.113110","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T08:47:50Z","timestamp":1653036470000},"page":"113110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Hydrogel-based co-delivery of CIK cells and oncolytic adenovirus armed with IL12 and IL15 for cancer immunotherapy"],"prefix":"10.1016","volume":"151","author":[{"given":"Ya-nan","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-qing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-rong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113110_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.113110_bib2","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ymthe.2018.04.001","article-title":"Oncolytic virus combination therapy: killing one bird with two stones","volume":"26","author":"Martin","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2022.113110_bib3","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3389\/fimmu.2017.00774","article-title":"Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy","volume":"8","author":"Gao","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2022.113110_bib4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s13046-021-02184-2","article-title":"30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective","volume":"40","author":"Sharma","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2022.113110_bib5","doi-asserted-by":"crossref","first-page":"8863","DOI":"10.1002\/jcb.28250","article-title":"Promising immunotherapy: Highlighting cytokine-induced killer cells","volume":"120","author":"Shirjang","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.biopha.2022.113110_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2022.113110_bib7","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.ymthe.2021.04.015","article-title":"Beyond cancer cells: targeting the tumor microenvironment with gene therapy and armed oncolytic virus","volume":"29","author":"Wan","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2022.113110_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107318","article-title":"Biological effects of IL-15 on immune cells and its potential for the treatment of cancer","volume":"91","author":"Zhang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2022.113110_bib9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.113110_bib10","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1038\/s41467-019-12794-2","article-title":"Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy","volume":"10","author":"Huang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2022.113110_bib11","article-title":"Oncolytic adenovirus: prospects for cancer immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.biopha.2022.113110_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cytogfr.2020.10.007","article-title":"Cytokines in oncolytic virotherapy","volume":"56","author":"Pol","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.biopha.2022.113110_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000710","article-title":"Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety","volume":"8","author":"Ge","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2022.113110_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12943-020-01275-6","article-title":"Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2022.113110_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2022.113110_bib16","article-title":"Combining IL-10 and oncolytic adenovirus demonstrates enhanced antitumor efficacy through CD8(+) T cells","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2022.113110_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910522","article-title":"Concepts in oncolytic adenovirus therapy","volume":"22","author":"Mantwill","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113110_bib18","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2022.113110_bib19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ymthe.2020.01.003","article-title":"Immune modulation by telomerase-specific oncolytic adenovirus synergistically enhances antitumor efficacy with anti-PD1 antibody","volume":"28","author":"Kanaya","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2022.113110_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2020.05.015","article-title":"Elimination of MYCN-amplified neuroblastoma cells by telomerase-targeted oncolytic virus via MYCN suppression","volume":"18","author":"Tanimoto","year":"2020","journal-title":"Mol. Ther. - Oncol."},{"key":"10.1016\/j.biopha.2022.113110_bib21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ags3.12270","article-title":"Multidisciplinary oncolytic virotherapy for gastrointestinal cancer","volume":"3","author":"Fujiwara","year":"2019","journal-title":"Ann. Gastroenterol. Surg."},{"key":"10.1016\/j.biopha.2022.113110_bib22","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.ymthe.2018.07.013","article-title":"Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade","volume":"26","author":"Kowalsky","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2022.113110_bib23","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2022.113110_bib24","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/2326-6066.CIR-19-0338","article-title":"Radiotherapy cooperates with IL15 to induce antitumor immune responses","volume":"8","author":"Pilones","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2022.113110_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.imlet.2017.08.010","article-title":"The potential and promise of IL-15 in immuno-oncogenic therapies","volume":"190","author":"Robinson","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.biopha.2022.113110_bib26","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1158\/1078-0432.CCR-18-0381","article-title":"Revisiting interleukin-12 as a cancer immunotherapy agent","volume":"24","author":"Berraondo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2022.113110_bib27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2022.113110_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008021","article-title":"Combined in vitro IL-12 and IL-15 stimulation promotes cellular immune response in dogs with visceral leishmaniasis","volume":"14","author":"Costa","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.biopha.2022.113110_bib29","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.4049\/jimmunol.1701614","article-title":"IL-15 promotes polyfunctional NK cell responses to influenza by boosting IL-12 production","volume":"200","author":"Wagstaffe","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2022.113110_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13111953","article-title":"Advances in injectable in situ-forming hydrogels for intratumoral treatment","volume":"13","author":"Shin","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2022.113110_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cellimm.2017.06.002","article-title":"The combination of NK and CD8+T cells with CCL20\/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells","volume":"318","author":"Ye","year":"2017","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.biopha.2022.113110_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.biomaterials.2017.09.009","article-title":"A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response","volume":"147","author":"Jung","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2022.113110_bib33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2017.03.028","article-title":"Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy","volume":"259","author":"Oh","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2022.113110_bib34","article-title":"Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus","volume":"12","author":"Zhao","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.113110_bib35","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1517\/14712598.2014.900537","article-title":"An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells","volume":"14","author":"J\u00e4kel","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.biopha.2022.113110_bib36","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.intimp.2016.06.028","article-title":"Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21\/IL15 armed oncolytic adenovirus in TERT-positive tumor cells","volume":"38","author":"Ye","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2022.113110_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2022.113110_bib38","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.7150\/jca.51434","article-title":"Cytokine-induced killer cells carrying recombinant oncolytic adenovirus expressing p21Ras scFv inhibited liver cancer","volume":"12","author":"Dai","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.biopha.2022.113110_bib39","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2022.113110_bib40","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic viral therapy and the immune system: a double-edged sword against cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2022.113110_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020400","article-title":"Oncolytic virus encoding a master pro-inflammatory cytokine interleukin 12 in cancer immunotherapy","volume":"9","author":"Nguyen","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2022.113110_bib42","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1039\/C9BM00992B","article-title":"Physically crosslinked injectable hydrogels for long-term delivery of oncolytic adenoviruses for cancer treatment","volume":"7","author":"Le","year":"2019","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biopha.2022.113110_bib43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jconrel.2015.11.014","article-title":"Engineered in-situ depot-forming hydrogels for intratumoral drug delivery","volume":"220","author":"Fakhari","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2022.113110_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113110_bib45","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2022.113110_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119971","article-title":"Delivery systems for enhancing oncolytic adenoviruses efficacy","volume":"591","author":"Zhou","year":"2020","journal-title":"Int. J. Pharm."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222004991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222004991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:46:00Z","timestamp":1787597160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222004991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":46,"alternative-id":["S0753332222004991"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113110","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydrogel-based co-delivery of CIK cells and oncolytic adenovirus armed with IL12 and IL15 for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113110"}}